Locally Advanced and Metastatic Pancreatic Cancer: Survival analysis and prognostic factors in a case series

Abstract

Objective: Systemic treatment of advanced pancreatic adenocarcinoma has resulted in increased survival of patients, but real-life data are scarce, particularly in developing countries. This study aims to analyze the survival of patients with locally advanced, unresectable, or metastatic pancreatic cancer and factors related to better survival. Methods: an analytical study with a retrospective and prospective part of data from patients with locally advanced or metastatic pancreatic adenocarcinoma treated between January 2012 to December 2018 in the oncology department of the Real Hospital de Beneficência Portuguesa, in Recife (Brazil). Results: Thirty-five patients were assessed. The median age was 68 years old (71.4% = 65 years old), the majority was male (65.7%), with Eastern Cooperative Oncology Group (ECOG) 0 and 1 (65.7%) and metastatic disease (68.6%). The median overall survival was 13.93 months and was longer for patients with ECOG 0 or 1 (20.4 months; p=0.021), Neutrophil-lymphocyte ratio (NLR) <4 (15.63 months; p=0.029) and who received local therapy (23.68 months; p=0.006). Conclusion: An overall median survival, similar to that of other clinical studies, was observed. Such survival was even better in patients with a good clinical condition (ECOG 0 or 1), low NLR, and who received some local therapy.

Keywords

• Survival Analysis
• Prognosis
• Antineoplastic Combined Chemotherapy Protocols
• Pancreatic Neoplasms
• Adenocarcinoma
• Análise de sobrevivência
• Prognóstico
• Antineoplastic Combined Chemotherapy Protocols
• Neoplasias pancreáticas
• Adenocarcinoma